Zacks: KemPharm Inc (KMPH) Given $27.33 Average Target Price by Brokerages

Shares of KemPharm Inc (NASDAQ:KMPH) have received an average broker rating score of 0.00 () from the four analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and three have issued a strong buy recommendation on the company.

Brokerages have set a one year consensus price objective of $27.33 for the company and are expecting that the company will post ($0.61) earnings per share for the current quarter, according to Zacks. Zacks has also given KemPharm an industry rank of 96 out of 265 based on the ratings given to related companies.

Several brokerages have recently commented on KMPH. Oppenheimer Holdings Inc. set a $13.00 price objective on shares of KemPharm and gave the company a “buy” rating in a research report on Saturday, March 11th. Canaccord Genuity set a $7.00 price objective on shares of KemPharm and gave the company a “buy” rating in a research report on Sunday, March 12th. Zacks Investment Research upgraded shares of KemPharm from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research report on Tuesday, March 14th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $8.00 price objective on shares of KemPharm in a research report on Saturday, March 11th.

Your IP Address:

Shares of KemPharm (NASDAQ:KMPH) opened at 4.225 on Tuesday. The company’s market capitalization is $61.88 million. The firm has a 50-day moving average of $3.83 and a 200 day moving average of $3.91. KemPharm has a 1-year low of $2.90 and a 1-year high of $19.75.

KemPharm (NASDAQ:KMPH) last announced its quarterly earnings data on Thursday, March 9th. The specialty pharmaceutical company reported ($0.68) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.70) by $0.02. On average, analysts anticipate that KemPharm will post ($2.53) EPS for the current year.

Several hedge funds have recently made changes to their positions in the stock. Arete Wealth Advisors LLC increased its stake in shares of KemPharm by 0.8% in the third quarter. Arete Wealth Advisors LLC now owns 834,602 shares of the specialty pharmaceutical company’s stock valued at $3,747,000 after buying an additional 6,857 shares during the last quarter. Alyeska Investment Group L.P. increased its stake in shares of KemPharm by 3.2% in the fourth quarter. Alyeska Investment Group L.P. now owns 998,742 shares of the specialty pharmaceutical company’s stock valued at $2,946,000 after buying an additional 31,415 shares during the last quarter. Parkwood LLC increased its stake in shares of KemPharm by 369.3% in the third quarter. Parkwood LLC now owns 125,809 shares of the specialty pharmaceutical company’s stock valued at $565,000 after buying an additional 99,000 shares during the last quarter. Creative Planning increased its stake in shares of KemPharm by 4,571.3% in the third quarter. Creative Planning now owns 410,794 shares of the specialty pharmaceutical company’s stock valued at $1,844,000 after buying an additional 402,000 shares during the last quarter. Finally, DSC Advisors L.P. increased its stake in shares of KemPharm by 54.7% in the fourth quarter. DSC Advisors L.P. now owns 1,459,193 shares of the specialty pharmaceutical company’s stock valued at $4,305,000 after buying an additional 515,708 shares during the last quarter. Hedge funds and other institutional investors own 44.36% of the company’s stock.

KemPharm Company Profile

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

5 Day Chart for NASDAQ:KMPH

Get a free copy of the Zacks research report on KemPharm (KMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KemPharm Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply